ArticleTranslational cancer research2025
Circulating white blood cell traits, chemokines and small cell lung cancer risk: a Mendelian randomization study.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small cell lung cancer (SCLC) commonly originates in the context of persistent inflammation. The impact of white blood cell (WBC) counts and the presence of infiltrating inflammatory cytokines in relation to tumor initiation, progression, and treatment response in SCLC remains uncertain. To elucidate the potential relationships of circulating WBCs and chemokines with SCLC, we conducted a univariable (UVMR) and multivariable Mendelian randomization (MVMR) study. Methods: We conducted a two-sample Mendelian randomization (MR) investigation to evaluate the causal impact of circulating WBCs and chemokines on the risk of SCLC. The genetic data for SCLC were derived from a genome-wide association study (GWAS) involving 24,108 participants, including 2,664 cases and 21,444 controls of European ancestry. The genetic variances of circulating WBCs and chemokines were also from GWAS. In the analysis of UVMR, the primary method employed was the inverse variance weighted (IVW) method. To infer causality, robust adjusted profile scores, weighted median (WM), and MR Egger were employed as supplementary methods. To ensure the robustness of the MR results, sensitivity analyses, including the Cochran Results: Using two-sample MR, we found that genetic predisposition to CD45RA Conclusions: Using two-sample MR, we found that genetic predisposition to CD45RA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.